Story
Kioxia Shares Rebound on Report of Potential $10 Billion US Listing
Summary
Shares of the Japanese memory chipmaker rallied after reports it is considering an American Depositary Receipt (ADR) offering. The news helped the stock recover from a previous session's sell-off tied to concerns over AI-driven demand.
Shares of Kioxia Holdings Corp. rebounded sharply on Tuesday, gaining 2.2% to close at ¥51,690 in Tokyo trading. The rally was fueled by reports that the Japanese NAND flash memory producer is exploring a potential U.S. listing to raise at least $10 billion.
US Listing Plans
According to the reports, Kioxia is in discussions with Bank of America, Goldman Sachs, and JPMorgan about a potential American Depositary Receipt (ADR) offering. The listing, which could take place as early as 2027, has renewed investor focus on the company's long-term capital strategy and its efforts to broaden its investor base globally.
Reversal from AI-Driven Sell-Off
The gains mark a significant reversal from the previous session, when the stock fell sharply from ¥54,030 to a close of ¥50,590. Monday's decline was triggered by a joint statement from executives at Anthropic, OpenAI, and SpaceX urging a slowdown in artificial intelligence development, which sparked investor concern about the durability of future demand for memory chips.
AdThe sell-off was reportedly amplified by the stock breaking below a key technical support level. Tuesday's bounce suggests a reassessment of those fears, with the ADR news providing a company-specific catalyst for buyers to return to the stock.
Analyst Outlook and Market Context
The rebound was supported by a broadly constructive analyst consensus and a stabilizing market backdrop. Japanese equities recovered modestly from the prior day's tech-driven weakness, while U.S. markets were largely flat overnight.
- Analyst Rating: 15 of 16 analysts covering Kioxia maintain a "Buy" rating.
- Price Target: The consensus 12-month price target for the stock is approximately ¥110,944.
- 52-Week High: The stock remains significantly below its 52-week high of ¥112,700, indicating substantial room for recovery if concerns about AI demand prove to be overstated.
Read next
More on Stocks
Novo Nordisk, Orbis Medicines Ink $1.4 Billion Deal for Oral Cardiometabolic Drugs
Orbis Medicines and Novo Nordisk have entered a licensing collaboration potentially worth up to $1.4 billion to develop oral versions of injectable drugs for cardiometabolic diseases, leveraging Orbis's AI-driven discovery platform.
Robinhood Shares Rise After SEC Issues Guidance on Tokenized Securities
Shares of Robinhood Markets (HOOD) climbed after the U.S. Securities and Exchange Commission introduced a five-year plan allowing for the trading of tokenized stocks on designated venues.
Gold Prices Face Near-Term Pressure From Strong US Data, Higher Yields
Gold is trading in a narrow range as robust economic indicators bolster Treasury yields, creating headwinds for the non-yielding asset. The medium-term outlook remains constructive, contingent on a potential shift in monetary policy and persistent structural demand.
UBS Upgrades Industrial Metals to Overweight, Citing Long-Term Structural Tailwinds
UBS has raised its outlook on industrial metals to Overweight, arguing that structural forces like the energy transition and chronic underinvestment will support prices in the coming years.